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Abstract
ELL-associated factor 2 (EAF2) is an androgen-responsive tumor suppressor frequently deleted in advanced prostate cancer
that functions as a transcription elongation factor of RNA Pol II through interaction with the ELL family proteins. EAF2
knockout mice on a 129P2/OLA-C57BL/6J background developed late-onset lung adenocarcinoma, hepatocellular
carcinoma, B-cell lymphoma and high-grade prostatic intraepithelial neoplasia. In order to further characterize the role
of EAF2 in the development of prostatic defects, the effects of EAF2 loss were compared in different murine strains. In the
current study, aged EAF22/2 mice on both the C57BL/6J and FVB/NJ backgrounds exhibited mPIN lesions as previously
reported on a 129P2/OLA-C57BL/6J background. In contrast to the 129P2/OLA-C57BL/6J mixed genetic background, the
mPIN lesions in C57BL/6J and FVB/NJ EAF22/2 mice were associated with stromal defects characteristic of a reactive stroma
and a statistically significant increase in prostate microvessel density. Stromal inflammation and increased microvessel
density was evident in EAF2-deficient mice on a pure C57BL/6J background at an early age and preceded the development
of the histologic epithelial hyperplasia and neoplasia found in the prostates of older EAF22/2 animals. Mice deficient in
EAF2 had an increased recovery rate and a decreased overall response to the effects of androgen deprivation. EAF2
expression in human cancer was significantly down-regulated and microvessel density was significantly increased compared
to matched normal prostate tissue; furthermore EAF2 expression was negatively correlated with microvessel density. These
results suggest that the EAF2 knockout mouse on the C57BL/6J and FVB/NJ genetic backgrounds provides a model of PIN
lesions associated with an altered prostate microvasculature and reactive stromal compartment corresponding to that
reported in human prostate tumors.
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Introduction
The prostate gland is tightly regulated by androgens and
consists of acini lined by secretory luminal cells and an underlying
layer of basal cells embedded within a fibromuscular stroma. In
the normal prostate, stromal cells direct epithelial differentiation
and development through growth factors and androgen stimula-
tion [1]. During prostate carcinogenesis, the stromal cells
immediately adjacent to prostate tumor cells are characterized
by a modified extracellular matrix, increased microvessel density
and a myofibroblastic phenotype [2]. The evolution of this reactive
stroma and its role in prostate disease development is not yet fully
understood, however, evidence of altered stroma has been
identified in precancerous prostatic intraepithelial neoplasia
(PIN) lesions as well as in prostate tumors [3,4]. Greater
understanding of the role of genes in regulating the stromal and
vascular microenvironment could provide insight into the mech-
anisms of early prostate disease development as well as progression
and metastasis.
ELL-associated factor 2 (EAF2) is a potential tumor suppressor
gene that was found to be up-regulated in response to androgens in
the rat ventral prostate [5] and in the human prostate cancer cell
line LNCaP [6]. EAF2 interacts with the RNA polymerase II (pol
II) elongation factor eleven-nineteen lysine-rich in leukemia (ELL)
in the regulation of transcription elongation [7]. EAF2 protein
down-regulation, allelic loss, promoter hypermethylation and
possibly homozygous deletion was identified in,80% of advanced
prostate cancer specimens examined (Gleason $7) [6]. Overex-
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pression of EAF2 in prostate cancer cell lines induced apoptosis
and inhibited the growth of xenograft tumors [6]. EAF2 knockout
mice developed lung adenocarcinoma, hepatocellular carcinoma,
B-cell lymphoma and high-grade murine prostatic intraepithelial
neoplasia (mPIN) [8]. In addition, EAF2 loss in a murine model
was found to increase microvessel density in aged animals and to
enhance the angiogenic effects of Von Hippel-Lindau (VHL)
heterozygosity in the liver and prostate [9]. Prostates of aged
EAF22/2 VHL+/2 mice displayed increased mPIN, stromal
inflammation, fibrosis and smooth muscle proliferation. PIN and
hepatic vascular lesions in EAF22/2 VHL+/2 animals were
characterized by decreased expression of pVHL, suggesting that
EAF2 enhanced the angiogenic effects of VHL heterozygosity [9].
EAF2 has also recently been shown to regulate the potent anti-
angiogenic factor thrombospondin 1 (TSP-1) through interaction
with the tumor suppressor p53, suggesting a role for EAF2 in TSP-
1 regulated angiogenesis [10]. TSP-1 inhibits the proliferation and
migration of endothelial cells and increases apoptosis [11].
Furthermore, decreased expression of TSP-1 has been reported
in prostate cancer [12]. In androgen-dependent prostate tumors,
TSP-1 expression is inversely correlated with microvessel density
(MVD) [13–15]. In the prostates of young EAF2 knockout
animals, TSP-1 expression was significantly reduced compared
to wild-type controls [10]. Additionally, overexpression of EAF2
and p53 in LNCaP and H1299 cells increased TSP-1 promoter
activity, suggesting that EAF2 and p53 could functionally interact
in the repression of angiogenesis through up-regulation of TSP-1
[10]. Interaction of EAF2 with its binding partners p53 and VHL
in the regulation of pro-angiogenic HIF1a and anti-angiogenic
TSP-1 may be critical for maintaining normal prostate homeo-
stasis. Dysregulation of these interacting pathways could promote
increased vascularization, cellular proliferation and prostate
tumorigenesis.
In the current study, the relationship between EAF2 loss and the
development of PIN lesions and increased microvasculature was
further explored. EAF2 knockout mice were generated on a pure
C57BL/6J or a pure FVB/NJ background and examined at
various ages for histological defects in the prostate. EAF2-
deficiency on either background was associated with an increase
in epithelial cell proliferation, the development of mPIN lesions as
well as an associated increased incidence in reactive stroma and
increased vascularity. Prostate stromal cells isolated from EAF22/
2 animals at age 15 mos were characterized by decreased growth
rate compared to wild-type controls. Furthermore, EAF2 expres-
sion was negatively correlated with microvessel density in human
prostate tissue specimens. These findings suggest that the
development of PIN lesions in the murine EAF22/2 mouse is
associated with the development of a reactive stroma that is similar
to that reported in human prostate cancer.
Materials and Methods
Generation of EAF2 Deletion Mice
Preparation of mice with specific deletion of the EAF2 gene has
been described previously [8,10]. Heterozygous EAF2+/2 mice
were initially generated using HM1 embryonic stem cells [8], and
were subsequently backcrossed to the C57BL/6J and FVB/NJ
strains (The Jackson Laboratory, Bar Harbor, ME, USA) for .12
generations to generate EAF22/2 mice with a pure C57BL/6J
and a pure FVB/NJ background. Experimental cohorts were wild
type and homozygous C57BL/6J and FVB/NJ male littermates,
all mice were maintained identically. All animal studies were
reviewed and approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Pittsburgh and were
conducted in strict accordance with the standards for humane
animal care and use as set by the Animal Welfare Act and the
National Institutes of Health guidelines for the use of laboratory
animals. Genotyping was determined by PCR analysis of mouse
tail genomic DNA and confirmed on muscle DNA when animals
were euthanized as described [8]. Mice on a C57BL/6J
background were euthanized at 7 weeks (n = 18 males), 19 weeks
(n = 18 males), 12 mos (n = 18 males) and 20–24 mos (n = 19) of
age. Mice on an FVB/NJ background were euthanized for
histological analysis at 15–20 mos (n = 8). In order to determine
the effect of EAF2 loss on response to androgen deprivation, an
additional cohort of wild type and EAF22/2 mice on a pure
C57BL/6J background were subjected to bilateral orchiectomy at
19 weeks of age and euthanized 3 days (n = 6) and 14 days post-
castration (n = 9). Tissue necropsy was performed and organs were
cleaned of excess fat and membrane with phosphate-buffered
saline; mass was determined after blotting with filtration paper to
remove excess water. Samples were fixed in 10% formalin for at
least 24 hrs, then embedded in paraffin, sectioned at 5 mm, and
stained with hematoxylin and eosin. All tissues were examined by
2 animal pathologists in a blinded fashion (LHR, V.M.D, BWS,
D.V.M.) and confirmed by a pathologist (MMI, M.D., Ph.D.).
Cell Culture
Cohorts of 3 wild-type and 3 EAF22/2 C57BL/6J mice at 4
mos of age, and 5 wild-type and 5 EAF22/2 FVB/NJ mice at 15
mos of age were euthanized and the anterior prostates were
isolated for in vitro experiments. Anterior prostate lobes were
microdissected from the urogenital tract and minced gently.
Minced tissue was digested by 1 hr incubation at 37uC in 2.4 U/
ml Dispase II (Roche Applied Science, Indianapolis, IN) in RPMI-
1640 media on a rocker. The resultant cell suspension was
aspirated with an 18-gauge needle and then cultured in DMEM
with 10% FBS, 0.1 mmol/L nonessential amino acids (Invitrogen),
100 mmol/L 2-mercaptoethanol (Sigma), and penicillin/strepto-
mycin. Anterior prostate epithelial and stromal cell mixtures were
used at passage 1, subsequent passages 2–5 were used as enriched
stromal cell populations. Lung stromal cells were isolated similarly
for use as non-androgen-responsive control cells.
Growth curves were plotted to evaluate population growth of
isolated stromal cells; characterization was performed at passages
2–5 in 12-well plates in triplicate, with seeding density of 16105
cells/well at day 0. Cells were harvested and counted with a
haemocytometer on days 3, 5 and 9, and results plotted on a linear
scale. The cell population doubling time was calculated during the
logarithmic growth phase with Doubling Time Software v1.0.10
(Roth, 2006, http://www.doubling-time.com/compute.php).
Each experiment was performed in triplicate and repeated a
minimum of 3 times.
Human prostate carcinoma cell line C4-2, initially derived from
a tumor xenograft induced by co-inoculating LNCaP prostate
cancer sublines with bone stromal cells [16], was kindly provided
by Dr. Leland W.K. Chung. Conditioned medium was obtained
from wild-type and EAF22/2 stromal cells at passages 2–4
cultured for 3–6 days to a confluency of ,75%. C4-2 cells were
plated at a density of 16105 cells/well in 12-well plates with 1 ml
of stromal conditioned media from either wild-type or EAF22/2
stromal cells at a confluency of ,75%. Media was replaced with
fresh stromal conditioned medium every 3 days. Cells were
harvested and counted with a haemocytometer on days 2, 5 and 7.
Results were plotted on a linear scale. Experiments were
performed in triplicate a minimum of 3 separate times.
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In situ Hybridization
Before hybridization, murine prostate tissue cryosections
(ProbeOn, Fisher Biotech, Pittsburgh, PA) were washed with
PBS, fixed in 4% paraformaldehyde, digested with proteinase K at
20 mg/ml in PBS, refixed in 4% paraformaldehyde, rewashed in
PBS, and then acetylated in 0.25% acetic anhydride in 0.1 M
triethanolamine, pH 8.0. Full-length EAF2 cDNA was inserted
into the EcoRI and XhoI site between T3 and T7 promoters in
pBluescript II SK plasmid vector. The plasmid was purified by
CsCl double banding, linearized with EcoRI or XhoI, and
proteinase K-treated. Purified linear DNA templates were used in
the synthesis of both sense and antisense digoxygenin-labeled
riboprobes using either T3 or T7 RNA polymerase (Promega
Corp., Madison, WI) as previously described [17,18]. Riboprobe
size was reduced to approximately 250 bp using limited alkaline
hydrolysis.
For hybridization, the probe was diluted in hybridization
solution (56SSC, 16Denhardt’s, 100 mg/ml salmon testis DNA,
50% formamide, and 250 mg/ml yeast transfer RNA), and slides
were hybridized overnight at 67uC in a sealed chamber humidified
with 56SSC/50% formamide. Coverslips were removed, and
slides were washed in 0.26SSC at 72uC for 1 h. After washing in
buffer (0.1 M Tris (pH 7.6), 0.15 M NaCl), slides were blocked in
10% horse serum at room temperature for 1 h. Slides were then
incubated overnight at 4uC with antidigoxigenin-AP Fab frag-
ments (1:2000, Boehringer Mannheim, Mannheim, Germany) in
1% horse serum. Slides were washed and then developed with
nitro blue tetrazolium (2.25 ml/ml) and 5-bromo-4-chloro-3-
indolyl-phosphate, 4-toluidine salt (0.6 mg/ml) in alkaline phos-
phatase buffer (0.1 M Tris (pH 9.5), 0.05 MMgCl2, 0.1 M NaCl).
Generation of EAF2 Monoclonal Antibody
GST-EAF2 fusion protein was generated by cloning human
EAF2 cDNA into pGEX-2T vector (Amersham-Pharmacia,
Piscataway, NJ). Female 6 week old BALB/c mice were
immunized 9 times with GST-EAF2. Hybridomas were generated
by fusing spleenocytes of an immunized mouse with mouse
myeloma cells P3-X63-Ag8.653 [19]. Culture supernatants from
antibody-secreting hybridoma cells were screened for specific
reactivity with EAF2 transfected cells by Western blot and
subcloned as described [20]. EAF2 mouse monoclonal antibodies
were purified from ascites fluid as described [21]. The purity of
EAF2 mouse monoclonal antibody preparations was assessed by
SDS-PAGE and the activity by western blot.
Human Prostate Tissue Specimens
Human prostate tissue specimens without any previous chemo-,
radio- or hormone therapy were obtained from the surgical
pathology archives by the University of Pittsburgh Prostate Tumor
Bank from de-identified tumor specimens consented for research
at time of treatment. Specimens included 14 matched prostate
cancer and benign prostate specimens adjacent to prostate cancer.
All cancer specimens were Gleason score$7. Use of these prostate
tissues was approved by the University of Pittsburgh Institutional
Review Board.
Immunohistochemistry
Immunohistochemical stains were performed on five-micron
sections of paraffin-embedded murine or human prostate tissue
specimens as described previously [22,23]. Briefly, sections were
deparaffinized and rehydrated through a graded series of ethanol.
Heat induced epitope retrieval was performed using a decloaker,
followed by rinsing in TBS buffer for 5 minutes. Primary
antibodies (working dilution 1:400) rat monoclonal anti-CD31
(MEC 13.3, 550274, BD Biosciences, San Jose, CA, USA), rat
monoclonal anti-Ki-67 (TEC-3, M7249, Dako, Carpinteria, CA,
USA), rabbit polyclonal anti-tenascin-C (TNC) (AB19013, Che-
micon, Billerica, MA, USA), goat polyclonal anti-ADAMTS-1 (L-
18, sc-5486, Santa Cruz), and rabbit polyclonal caspase 3 (H-277,
sc-7148, Santa Cruz Biotechnology) were used for immunostain-
ing of murine tissue sections. Primary antibodies anti-CD34
(QBEnd/10, 790–2927, Ventana, Tucson, AZ, USA), rabbit
polyclonal ADAMTS1 (NBP1-50161, Novus Biologicals, Littleton,
CO, USA) and an internally generated mouse monoclonal anti-
EAF2 were used for immunostaining of human prostate tissue
specimens. Slides were then counterstained in hematoxylin and
coverslipped. Immunostained sections were imaged with a Leica
DM LB microscope (Leica Microsystems Inc, Bannockburn, IL,
USA) equipped with a QImaging MicroPublisher 3.3 RTV digital
camera (QImaging, Surry, BC, Canada).
For murine tissues, CD31-positive vessel density and Ki-67-
positive cell density in were determined by analysis of sections
from at least 3 independent mice from each genotype. Assessment
of microvessel density was determined based on CD31-positive
vessel count as described [9]; proliferative index was determined
based on cell count as described [24]. Microvessel density for each
group was determined from at least 20 fields imaged at 20X
magnification with no overlap and identified by evaluating
histological sections, and CD-31-positive vessels were counted to
determine the average vessel numbers per field for each section.
One section for each mouse was quantified. Proliferative index in
mice on a C57BL/6J background was determined from at least 20
fields imaged at 20X magnification with no overlap. Ki-67-positive
prostate epithelial cells were counted to determine the average
number of proliferating cells for each section. For mice on an
FVB/NJ background, slides stained with Ki-67 were scanned and
digitized using the Aperio ScanScope CS scanner (Aperio, Vista,
CA) to capture digital whole slide images (WSI) using the 620
objective lens at a spatial sampling period of 0.47 mm per pixel.
The digital WSI were analyzed using Aperio ImageScope software
(http://www.aperio.com/pathology-services/image-scope-slide-
viewing -software.asp). The manufacturer’s (Aperio Technologies,
Inc.) algorithms were used to quantify nuclear staining.
For human prostate tissue specimens, CD34-positive vessel
density was determined by analysis of prostate cancer specimens
and matched benign prostate adjacent to prostate cancer
specimens. Microvessel density was determined by counting the
total number of CD34-positive vessels in at least 3 fields at 20X
magnification. EAF2 and ADAMTS1 staining intensities were
evaluated semi-quantitatively. The percentage of prostate epithe-
lial cells of a specific histological phenotype (normal and cancer)
that expressed the antigen was estimated in three randomly
selected fields at a final magnification of 40X. Staining intensity
was evaluated by two parameters (staining intensity and percent-
age of cells exhibiting each level of intensity). Intensity of reaction
product was based on a 4-point scale – none, faint/equivocal,
moderate and intense. An H-Score was calculated for each
immunostain by cell type using the following formula:
H-Score = 0(% no stain) + 1(% faint/equivocal) + 2(%
moderate) + 3(% intense). All tissues were examined by a
pathologist in a blinded fashion (AVP, M.D., Ph.D.).
Laser-capture Microdissection and Quantitative PCR
Murine samples were processed as described previously [25],
using the Cells DirectTM OneStep qPCR kit from Invitrogen
(Carlsbad, CA) according to manufacturer’s protocol including
DNAse digestion step to ensure that starting material included no
Prostate Reactive Stroma in EAF2 Knockout Mice
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genomic DNA. Human prostate tumor specimens without any
previous chemo-, radio- or hormone therapy were sectioned and
evaluated by a board-certified pathologist (AJP). Prostate cancer
cells and adjacent normal glandular cells were isolated by laser-
capture microdissection using a Leica LMD6000 Microsystems
microscope (Wetzlar, Germany) equipped with a HV-D20P
Hitachi (Tokyo, Japan) color camera and Leica Laser Microdis-
section V 6.3 imaging software (Wetzlar, Germany). Primers were
designed to span exon exon junctions using PrimerBank [26] or
Primer3 software (Totowa, NJ,) and optimized to within 98–102%
efficiency. Efficiencies were incorporated into calculations for
qPCR using the DCp (crossing point) method (R= 2[Cp sample – Cp
control]) in which the relative expression ratio (R) for each sample
was to GAPDH. Primers used are listed in Table 1. All assays were
run on an ABI Step-One Plus thermocycler (Applied Biosystems
Inc., Carlsbad, CA).
Statistical Analysis
Comparison between groups were calculated using the
Student’s t-test, the two-tailed Fisher’s exact test method of
summing small p values, the 1-way and 2-way ANOVA and
Bonferonni’s Multiple Comparison Test as appropriate. Pearson
correlation and Spearman Coefficient were calculated for immu-
nostaining intensity of EAF2 and CD34-positive microvessel
density in human prostate tissue specimens and categorized as
follows: no correlation (0.00 to 0.30), moderate correlation (0.31 to
0.79), strong correlation (0.80 to 0.99). A value of p,0.05 was
considered significant. GraphPad Prism version 4 was used for
graphics (GraphPad Software, San Diego, CA, USA). Values are
expressed as means 6 S.E.M.
Results
EAF2-deficiency Induces a Reactive Stroma and PIN
Lesions in Aged C57BL/6J and FVB/NJ Mice
EAF22/2 mice were generated on a pure C57BL/6J or a pure
FVB/NJ background in order to determine the potential effects of
different genetic backgrounds on the prostate phenotype. All
genetic backgrounds examined had a statistically significant
increased incidence in mPIN lesions in EAF22/2 animals
compared to wild-type controls at 20–24 mos of age (Fig. 1A).
On a 129P2/OLA-C57BL/6J genetic background, mPIN lesions
were reported in 8 out of 15 (53%) EAF22/2 animals at age 24
mos [8]. Similarly, EAF22/2 mice on a pure C57BL6/J
background developed mPIN lesions in 10 out of 12 (83.3%,
p,0.05) and in 3 out of 4 (75%, p= 0.1429) FVB/NJ animals at
age 20–24 mos compared to wild-type controls (Fig. 1A). There
was no statistically significant difference in mPIN incidence among
the strains. No wild-type animals displayed mPIN lesions in any
strain. One striking difference apparently influenced by genetic
background was the lack of macroscopic tumors in other organs of
aged mice on a C57BL/6J and FVB/NJ background, suggesting
that genetic background has a significant impact on carcinogenesis
induced by EAF2 loss. Another difference was in the incidence of
prostate stromal abnormalities in aged C57BL/6J and FVB/NJ
EAF22/2 animals associated with PIN lesions that were charac-
teristic of a reactive stroma (Fig. 1B). Prostate reactive stroma is
characterized by decreased smooth muscle differentiation, in-
creased myofibroblasts and fibroblasts and an increase in
extracellular matrix remodeling [3]. Stromal defects were not
previously reported in EAF22/2 mice on a 129P2/OLA-C57BL/
6J background [8]. Re-examination of the prostates from 129P2/
OLA-C57BL/6J background mice by a board certified animal
pathologist (L.H.R.) verified the lack of stromal abnormalities in
either EAF22/2 or wild-type animals on a 129P2/OLA-C57BL/
6J background (Fig. 1C). However, all of the C57BL6/J (10/12)
and FVB/NJ (3/4) EAF22/2 mice displaying mPIN lesions at age
20–24 mos also displayed stromal abnormalities when compared
to wild-type controls (Fig. 1D, E). The mPIN lesions in EAF22/2
animals on a pure C57BL/6J or FVB/NJ background were
characterized by increased stromal hypertrophy and hyperplasia,
increased lymphatic dilation and chronic inflammation compared
to age-matched wild-type controls (Fig. 1 D, E). Furthermore,
EAF22/2 animals on a C57BL/6J background displayed areas of
moderate to intense stromal immunopositivity for reactive stroma
marker tenascin-C (TNC) [3,27], whereas wild-type animals
displayed no immunopositivity for TNC expression (Fig. 1F).
Age-related mild multifocal lymphocytic interstitial infiltrates were
observed in all of the C57BL/6J and FVB/NJ wild-type and
EAF22/2 prostates of mice at 20–24 mos (data not shown). The
development of a reactive stroma in the C57BL6/J and FVB/NJ
but not the 129P2/OLA-C57BL/6J suggests that genetic back-
ground influences the EAF2 knockout prostate phenotype.
Temporal Development of Prostate Stromal and
Epithelial Defects in EAF2-Deficient Mice
In order to further characterize the effects of EAF2 loss on the
development of prostate epithelial defects and the development of
a reactive stroma, the prostates of C57BL/6J wild-type and
EAF22/2 mice were examined at age 7 weeks, and 19 weeks
(n = 9 per group). Prostate abnormalities including epithelial
hypertrophy, hyperplasia and dysplasia were previously reported
Table 1. Primers for qPCR.
Gene Forward Reverse Species
ADAMTS1 CATTAACGGACACCCTGCTT CGTGGGACACACATTTCAAG mouse
ADAMTS1 GCTCATCTGCCAAGCCAAAG CTACAACCTTGGGCTGCAAAA human
CD90 TGCTCTCAGTCTTGCAGGTG TGGATGGAGTTATCCTTGGTGTT mouse
EAF2 GGATTGGCATGTTTGCAGTTC ACTGGATTCTGCTACTCCCTTC mouse
EAF2 CCAGGACTCCCAATCTTGTAAA TAGCTTCTGCCTTCAGTTCTCTT human
GAPDH AGGTCGGTGTGAACGGATTTG GTAGACCATGTAGTTGAGGTCA mouse
GAPDH CATGTTCGTCATGGGTGTGA GGTGCTAAGCAGTTGGTGGT human
MMP9 CTGGACAGCCAGACACTAAAG CTCGCGGCAAGTCTTCAGAG mouse
OCN GACCGAGTGCGGTTCAAAG CGCAGGGCACATCCAACTT mouse
doi:10.1371/journal.pone.0079542.t001
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in EAF22/2 mice on a 129P2/OLA-C57BL/6J genetic back-
ground as early as 4–6 months of age [8]. On a C57BL/6J
background at age 7 weeks, no histological epithelial abnormalities
were detected in wild-type or EAF22/2 animals (Fig. 2A and Fig.
S1A). Two EAF22/2 animals had mild smooth muscle prolifer-
ation, fibroplasia and lymphocytic infiltration compared to wild-
Figure 1. EAF2-deficiency induces murine prostatic intraepithelial neoplasia (mPIN) and stromal defects in C57BL/6J and FVB/NJ
mice at age 20–24 mos. A. Strain-specific incidence rate of mPIN in EAF22/2 mice at age 20–24 mos compared to 0% incidence in wild-type (WT)
controls (*p,0.01). B. Strain-specific incidence in stromal defects in EAF22/2 mice at age 20–24 mos compared to 0% incidence in WT controls
(*p,0.01). Number of animals in each group is indicated in parenthesis. C. EAF22/2 mice on a 129P2/OLA-C57BL/6J background developed mPIN
lesions but not stromal defects (right panel inset, black arrow designating mPIN). D. Aged EAF22/2 mice on a C57BL/6J background displayed mPIN
and stromal hypertrophy (right panel, solid black arrow) and interstitial fibrosis (right panel inset, dashed arrow) at age 20–24 mos compared to WT
controls. E. Aged EAF22/2 mice on an FVB/NJ background displayed mPIN (right panel inset, solid black arrow) and increased stromal inflammation
and fibrosis (right panel inset, dashed black arrow) compared to WT controls. F. Prostate stromal cells surrounding mPIN lesions in aged EAF22/2
mice displayed immunopositivity for reactive stroma marker tenascin-C (TNC). Original magnification 10X, inset 40X. Scale bars indicate 200 micron in
10X, 50 micron in 40X. All images are ventral prostate lobe.
doi:10.1371/journal.pone.0079542.g001
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type animals (p = 0.47). By 19 weeks of age, 1 out of 9 EAF22/2
mice on a C57BL/6J background displayed small areas of prostate
epithelial hyperplasia (Fig. S1B, solid black arrow). However 9 out
of 9 (100%, p,0.0001) EAF22/2 mice displayed diffuse, evenly
distributed mild stromal inflammation (Fig. 2A and Fig. S1B,
dashed arrow). Compared to the wild-type prostate stroma,
EAF22/2 animals at age 19 weeks had increased edema,
lymphocytic infiltration, plasma cells, neutrophils, macrophages,
mast cells and fibroblasts. Microvessels in the prostates of EAF22/
2 mice were frequently associated with inflammation (Fig. S1B,
black arrowhead). The prostates of both wild-type and EAF22/2
mice displayed no immunopositivity for reactive stromal marker
TNC at age 19 weeks (data not shown).
EAF2 Deficient Mice have Increased Prostate Microvessel
Density
In order to further characterize the potential contribution of
increased microvessel density and cellular proliferation to the
development of epithelial defects in the EAF2-deficient murine
prostate, the number of CD31 positive vessels and Ki-67 positive
epithelial cells was quantified in wild-type and EAF22/2 animals
at ages 7 and 19 weeks on a pure C57BL/6J background. In
agreement with the lack of histological epithelial abnormalities in
EAF22/2 mice at ages 7 and 19 weeks (see Fig. 2A), there was no
significant difference in cellular proliferation between EAF22/2
and wild-type control animals (data not shown). Previously, the
prostates of EAF2 knockout mice on the C57BL/6J background
had statistically significant decreased expression of anti-angiogenic
TSP-1 at 3 mos of age [10], and an approximate 2-fold increase in
microvessel density age 20–24 mos [9]. While there was no
statistically significant difference in microvessel density detected at
Figure 2. Effects of EAF2 loss on C57BL/6J and FVB/NJ mouse prostate. A. Incidence in prostate epithelial hyperplasia (Epi) and stromal
defects (Str) in C57BL/6J EAF22/2 mice at age 7 wks and 19 wks compared to 0% incidence in age-matched wild-type controls. B. CD31+ microvessel
density in C57BL/6J wild-type (WT) and EAF22/2 mice at age 7 wks and 19 wks. Data represent average of 9 C57BL/6J mice per group. C. Percentage
of Ki-67 positive epithelial cells in the ventral (vp), dorsal-lateral (dlp), and anterior (ap) prostate of wild-type (WT), EAF2+/2 and EAF22/2 FVB/NJ mice
at age 20 mos. D. CD31+ microvessel density in FVB/NJ WT and EAF22/2 mice at age 20 mos. Data represent average of 3 FVB/NJ mice per group.
(*p,0.05, **p,0.001, ***p,0.0001).
doi:10.1371/journal.pone.0079542.g002
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age 7 weeks, a small but statistically significant increase in the
number of CD31-positive vessels per field was observed in the
prostates of 19-week old EAF22/2 mice as compared to wild-type
control animals (Fig. 2B and Fig. S1C). In agreement with
increased prostate epithelial cell proliferation and microvessel
density in aged mice on the C57BL/6J background [9], EAF22/2
FVB/NJ mice at 20 mos of age had a statistically significant
increase in Ki-67 positive cells and a statistically significant
increase in CD31+ vessels compared to age-matched wild-type
controls (Fig. 2C, D and Fig. S1D, E). Although not statistically
significant, EAF2+/2 FVB/NJ animals at 20 mos of age also had
an increased cellular proliferation, suggesting that heterozygous
loss of EAF2 could also contribute to the development of epithelial
defects. These results suggest that microvessel proliferation and
stromal inflammation could precede the development of prostate
epithelial abnormalities such as hyperplasia and PIN lesions. As
there was not a statistically significant increase in the incidence in
PIN lesions in the C57BL/6J (83.3%) and FVB/NJ EAF2 (75%)
knockout models compared to that of the 129P2/OLA-C57BL/6J
(53%), perhaps due to an insufficient sample size to determine this
endpoint, it is not clear whether the stromal defects contributed to
the development of PIN lesions in these mice. However, EAF2
knockout was associated with an increased incidence in murine
PIN lesions in all three of these strains.
Androgens regulate prostate growth in part through effects on
the vascular microenvironment [28,29]. In order to determine the
effects of androgen deprivation on prostate neovascularization,
cellular proliferation and apoptosis in the EAF2 knockout, mice
were castrated at age 19 weeks and euthanized at 3 and 14-days
post-castration. Human prostate cancer xenografts have been
shown to recover completely from vascular damage due to
androgen deprivation within 5–7 days [30]. In agreement with this
finding, wild-type and EAF22/2 animals had decreased prostate
vascularity at 3 days post-castration (Fig. 3A). At 14 days post-
castration, microvessel density had recovered in both wild-type
and EAF22/2 animals, suggesting that the murine prostate
vasculature responds similarly to xenograft tumors in response to
androgen deprivation (Fig. 3A and Fig. S2A). Compared to wild-
type controls, EAF22/2 mice had a decreased microvessel density
at 3 days post-castration and an increased microvessel density at
14 days post-castration. Furthermore, this fluctuation in vascular-
ity was statistically significant at both time points. At 3 days post-
castration, EAF22/2 was decreased 1.89-fold (p,0.001) and
increased 1.42-fold (p,0.01) compared to the microvessel density
of intact EAF22/2 mice. These results suggest that EAF2 plays a
significant role in the maintenance of the prostate vasculature even
in the absence of androgens.
In response to castration, the prostates of both wild-type and
EAF22/2 animals were involuted by day 14 and significantly
decreased in mass compared to intact controls. However, EAF22/
2 mice had a statistically significant increase in cell proliferation as
shown by an elevated number of Ki-67 positive cells (Fig. 3B and
Fig. S2B) and a statistically significant decrease in apoptosis as
shown by a decreased number of caspase-3-positive cells compared
to castrated wild-type at day 14 (Fig. 3C and Fig. S2C). Although
not statistically significant compared to wild-type controls,
EAF22/2 animals had a statistically significant response in
reduced vascularity and cellular proliferation at day 3 post-
castration compared to intact EAF22/2 animals. At day 14 post-
castration, the increased microvessel density, cellular proliferation
and reduced apoptosis suggested that EAF22/2 mice were less
responsive to castration-induced prostate involution. Taken
together, these results suggest that EAF2 loss may be associated
with an increased recovery rate and a decreased overall response
to the effects of androgen deprivation in the murine prostate.
Figure 3. Effects of castration on EAF2-deficient mice at age 19
wks. A. Quantification of CD31+ vessels in intact (0 days) and castrated
EAF22/2 mice vs wild-type (WT) controls on Day 3 and Day 14 post-
castration. B. Quantification of Ki-67+ cells in intact and castrated
EAF22/2 mice vs WT controls on Day 3 and Day 14 post-castration. C.
Quantification of caspase 3+ luminal epithelial cells in castrated EAF22/
2 mice vs WT controls on Day 3 and Day 14 post-castration. Data
represent average of at least 3 mice per group. (*p,0.05, ***p,0.001).
doi:10.1371/journal.pone.0079542.g003
Prostate Reactive Stroma in EAF2 Knockout Mice
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e79542
EAF2 Expression is Localized to the Epithelial Cell in
Murine Prostate
In human prostate tissue, EAF2 protein expression was
previously reported as confined to the epithelial cell [6]. In situ
hybridization was used to determine the cell type specific
expression of EAF2 mRNA in the wild-type murine prostate.
EAF2 mRNA expression was localized to prostate epithelial cells
with little to no expression in the stromal cells (Fig. 4A). In
addition, anterior prostate lobes were isolated from wild-type mice
at age 15 mos and cultured in vitro. Mixed prostate epithelial and
stromal cells were analyzed by qPCR at passage 1 and compared
to enriched stromal cell populations cultured in vitro for 2–4
passages by qPCR. Enriched stromal cells displayed the elongated
spindle-shaped morphology typical of cultured fibroblasts and
expressed stromal marker a-smooth muscle actin (aSMA) (Fig. 4B,
C). Analysis of EAF2 mRNA in the anterior prostate passage 1
mixed stromal and epithelial cell cultures compared to the passage
2–4 enriched stromal cell cultures demonstrated a decrease in
EAF2 expression in the stromal cells (Fig. 4D). These results
suggest that, in agreement with EAF2 expression in the human
prostate, EAF2 expression in the murine prostate is predominantly
localized to epithelial cells.
In order to further characterize the impact of EAF2 loss on the
prostate microenvironment, stromal cells were isolated and
cultured in vitro from the prostates of EAF22/2 and wild-type
C57BL/6J mice at age 19 weeks and C57BL/6J and FVB/NJ
mice at age 15 mos for 2–4 passages. Growth curves were not
statistically different in EAF22/2 C57BL/6J mice compared to
wild-type controls at age 19 weeks (data not shown), however
EAF22/2 FVB/NJ mice at 15 mos of age demonstrated a
statistically significant decreased growth rate compared to age-
matched wild-type controls (Fig. 5A, B). Similar decreased growth
rate was demonstrated by EAF22/2 C57BL/6J mice at 15 mos of
age (data not shown). Stromal cells isolated from both wild-type
and EAF22/2 mice from both strains became quiescent after
passage 4. In addition to prostate, EAF2 expression has been
identified in several adult murine tissues, including the adult brain,
spleen, liver, lung, thymus, and kidney [31]. Growth curves of lung
stromal cells were not statistically different in EAF22/2 compared
to wild-type FVB/NJ mice at 15 mos of age (Fig. 5C), suggesting
the growth difference in stromal cells isolated from the EAF2
knockout was prostate specific. Initiated human prostate epithelial
cells have an increased growth rate when co-cultured with cancer
associated fibroblasts compared to normal prostate stromal cells
[32]. Similarly, conditioned media from prostate stromal cells
isolated from aged EAF22/2 FVB/NJ mice induced a statistically
significant increased growth rate in C4-2 prostate cancer cells
compared to conditioned media from wild-type prostate stromal
Figure 4. Expression of EAF2 in the murine prostate. A. In situ hybridization analysis of EAF2 mRNA in murine prostate tissue. Both anti-sense
(upper panels) and sense (lower panels) EAF2 RNA probes were labeled with DIG and visualized with alkaline phosphatase-conjugated anti-DIG
antibody. Epithelial (E) and stromal (S) cells are indicated by arrows. AP, anterior prostate, DP, dorsal prostate, LP, lateral prostate, VP, ventral prostate.
Scale bars indicate 50 micron. B. Stromal cells isolated from the anterior prostate cultured in vitro at passage 3. C. Stromal cells express a-smooth
muscle actin (a-SMA). D. qPCR analysis of EAF2 expression in cultured mixed epithelial and stromal cells isolated and from wild-type AP (WT AP)
compared to wild-type stromal cells (WT Str). Data are normalized to GAPDH. Data represent average of 3 animals per cohort.
doi:10.1371/journal.pone.0079542.g004
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cells, suggesting that the altered stromal microenvironment
induced by EAF2 loss in aged animals could stimulate epithelial
cell growth through paracrine signaling (Fig. 5D).
Decreased Expression of ADAMTS1 in EAF22/2 Mice
Since EAF2 in murine prostate is expressed by epithelial cells
(see Fig. 5), signals inducing the modified EAF22/2 prostate
stromal and vascular microenvironment could be paracrine. The
prostate stromal microenvironment has been postulated to limit
tumor growth through the up-regulation of genes inhibiting
proliferation and angiogenesis, including ADAMTS1 [33].
ADAMTS1 is a secreted protein that acts as an inhibitor of
angiogenesis, invasion and metastasis. Normal prostate stromal
cells isolated from human tissue specimens have been shown to
induce the up-regulation of several genes encoding secreted
proteins including ADAM metallopeptidase with thrombospondin
(TSP) type I motif, 1 (ADAMTS1) whereas CD90+ cancer
associated stromal fibroblasts did not [34]. Furthermore, Altered
ADAMTS1 expression was not identified as differentially
expressed in microarray analyses of young EAF22/2 mice [35]
or in qPCR analyses of murine prostate at age 19 weeks (data not
shown), suggesting that EAF2 does not directly regulate
ADAMTS1 expression. Although not statistically significant,
analysis of FVB/NJ murine prostate stromal cells isolated from
mice at 15 mos of age revealed an increase in mRNA expression in
CD90 (p = 0.096) and a decrease in ADAMTS1 (p = 0.0582) in
EAF22/2 mice compared to wild-type controls (data not shown).
Genetic background can have a significant impact on prostate
tumor development in mice [36,37], and mPIN lesions were more
frequently observed in C57BL/6 and FVB/N strains than in the
129/SvImJ background (reported in [38]). In an analysis of
prostate transcriptomes from multiple genetic strains, ADAMTS1
was among the most differentially expressed [38]. Baseline
differences in the expression of genes that can either contribute
to or inhibit tumor initiation and progression can have a
significant impact on knockout phenotype. The development of
a reactive stroma in the EAF22/2 mice on the C57BL/6J and
FVB/NJ genetic backgrounds but not 129P2/OLA-C57BL/6J
could be due in part to secondary strain-specific differences that
exacerbate the effects of EAF2 loss in the prostate microenviron-
ment.
Figure 5. Growth characteristics of stromal cells isolated from wild-type and EAF22/2mice. A. Growth curve analysis (in days) of cultured
prostate stromal cells isolated from wild-type (WT) and EAF22/2 FVB/NJ mice at age 15 mos. B. Stromal cells cultured in vitro from WT and EAF22/2
mice. C. Growth curve analysis of cultured lung stromal cells isolated from WT and EAF22/2 FVB/NJ mice at age 15 mos. D. Growth curve analysis of
C4-2 cells grown in prostate stromal cell-conditioned media from WT and EAF22/2 FVB/NJ mice at age 15 mos. Data represent average a minimum of
3 animals per cohort and at least 3 technical replicates representative of 3 different experiments (*p,0.05, **p,0.001, ***p,0.0001).
doi:10.1371/journal.pone.0079542.g005
Prostate Reactive Stroma in EAF2 Knockout Mice
PLOS ONE | www.plosone.org 9 November 2013 | Volume 8 | Issue 11 | e79542
EAF2 Expression is Negatively Correlated with
Microvessel Density in Human Prostate Cancer Tissue
Specimens
EAF2 has previously been shown to be down-regulated in
human prostate cancer specimens [6]. ADAMTS1 expression is
also decreased in human prostate cancer [39]. In order to further
examine the potential correlation of EAF2 and ADAMTS1 in
human prostate cancer, mRNA levels of EAF2 and ADAMTS1
were analyzed in laser capture microdissected human prostate
tissue specimens (Fig. 6A, B and Fig. S3A). Additionally, the
expression intensity of EAF2, ADAMTS1 and the number of
CD34-positive microvessels was also examined in human prostate
tissue specimens by immunostaining (Fig. S3B). Both EAF2 and
ADAMTS1 mRNA expression levels were significantly reduced in
prostate cancer tissues compared to normal adjacent tissue (see
Fig. 6A, B). Expression levels of EAF2 did not correlate with
ADAMTS1 expression levels (data not shown) further suggesting
that EAF2 does not directly regulate ADAMTS1 mRNA
expression in the prostate.
Semi-quantitative analysis of immunostaining intensity revealed
a negative correlation between EAF2 and the number of CD34-
positive vessels in human prostate specimens. Compared to
matched benign tissues, EAF2 staining intensity was significantly
reduced in prostate cancer tissues while microvessel density was
increased (Fig. 6C, D and Fig. S3). The Pearson correlation was
20.651 (p= 0.003) and Spearman Coefficient was 20.623
(p = 0.006) indicating a moderate negative correlation between
EAF2 expression and CD34-positive microvessel density (Fig. 6E).
The negative correlation of EAF2 expression and microvessel
density in human prostate tissue specimens was in agreement with
the increased vascularity observed in the EAF2 knockout mice,
suggesting that EAF2 plays an important role in the regulation of
prostate vascularity in both normal and malignant tissues.
Discussion
Prostate stromal-epithelial interactions are critical for both
development and maintenance of prostate homeostasis. Although
the specific mechanisms that induce the development of a cancer-
associated or ‘‘reactive’’ stroma are not fully understood,
alterations in the prostate stroma have been associated with mPIN
lesions in mice [40], and the development of a reactive stroma has
been associated with the development of early PIN as well as
cancer in human prostate [3,41]. The presence of a reactive
stroma in prostate cancer has been associated with biochemical
recurrence, and has been also correlated with risk of prostate
cancer specific death [42,43]. In the current study, EAF2-
deficiency in mice induced an increased incidence in prostatic
intraepithelial neoplasia in a panel of murine strains. In addition to
mPIN lesions, aged EAF22/2 C57BL/6J and FVB/NJ mice also
developed a statistically significant increase in prostate stromal
defects characteristic of a reactive stroma, including hyperplasia,
fibroplasia, increased microvessel density and increased expression
of reactive and cancer-associated fibroblast stroma markers TNC.
Mild prostate stromal inflammation was displayed by EAF22/2
animals as early as 19 weeks of age and preceded the development
of the increased epithelial cell proliferation displayed by older
EAF22/2 animals.
Previously, EAF22/2 mice on a mixed 129P2/OLA-C57BL/6J
genetic background showed significantly enhanced neovascular-
ization in Matrigel plug angiogenesis assays [44]. Furthermore,
male mice on a C57BL/6J background at 20–24 months of age
displayed a statistically significant increase in microvessel density
in the prostate [9]. In agreement with these previous studies, the
EAF2 knockout model exhibited significantly increased prostate
microvessel density in aged animals from the FVB/NJ strain.
Previous studies have demonstrated that EAF2 loss in C57BL/6J
mice was associated with a significant decrease in the expression of
anti-angiogenic TSP-1 as early as 3 mos of age [10]. EAF2
knockout mice have also been shown to have increased levels of
HIF1a at 12 mos of age [9]. Indeed, by 19 weeks of age, C57BL/
6J mice displayed a statistically significant increased prostate
vascularization in EAF2-deficient animals, and this increased
vascularity appeared to precede the development of prostate
epithelial hyperplasia and mPIN lesions in the aged EAF2
knockout model. Furthermore, microvessel density and cellular
proliferation was also increased in the prostates of castrated
EAF22/2 animals compared to wild-type controls, suggesting that
the EAF22/2 prostate was less responsive to castration than wild-
type.
Stromal influence on prostate tumor development and progres-
sion is not completely understood. Previous studies have demon-
strated that stromal cells are capable of regulating angiogenesis in
prostate tumors [45]. However, it is clear that the luminal
epithelial cell also plays an important role. Similar to human
prostate, EAF2 expression is confined to the epithelial cell in the
murine prostate. In the current study, EAF2 loss was associated
with increased incidence in mPIN lesions and increased vascularity
in 3 murine strains and EAF2 down-regulation was associated with
increased vascularity in human prostate tumors specimens.
Furthermore, the EAF22/2 murine prostate vasculature and
epithelial cell proliferation responded to and recovered from
castration more quickly than wild-type prostate. Recently, we
reported that EAF2 down-regulation was more frequently
observed in tumors with Gleason scores 8–9 than in Gleason
score of 7 or lower [46]. Prostate tumor angiogenesis and cell
proliferation are also positively correlated with Gleason score
[47,48]. These observations suggest that EAF2 can modulate
prostate vascularity and epithelial cell proliferation, and loss of
EAF2 in prostate tumors might contribute to progression and
castration resistance.
On the C57BL/6J and FVB/NJ backgrounds, aged EAF22/2
mice displayed increased incidence in mPIN lesions compared to
wild-type controls as well as stromal defects characteristic of
cancer-associated fibroblasts. In human prostate, it has been
hypothesized that increasing cellular senescence in the aging
prostate could induce remodeling of the prostatic stroma towards a
more reactive phenotype [49]. Prostate stromal cells isolated from
EAF22/2 prostates and grown in culture had a statistically
significant decreased growth rate compared to age-matched wild-
type controls, whereas the growth rate of lung stromal cells was not
altered. Prostate cancer-associated fibroblasts isolated from human
tissues stimulate epithelial cell proliferation, whereas normal
prostate stromal cells inhibit epithelial proliferation [32]. Similarly,
EAF22/2 prostate stromal cells also induced an increased growth
rate in C4-2 cells compared to wild-type stromal cells. This finding
suggests that reactive stroma in the EAF2 knockout mouse is
functionally important and could promote prostate carcinogenesis.
EAF2 knockout mice on the C57BL/6J or FVB/NJ background
provide an in vivo model to study reactive stroma in early prostate
carcinogenesis.
Prostate cancer-associated fibroblasts in human tissues have
been identified by strong CD90 immunostaining [50]. In a co-
culture assay, CD90+ prostate cancer-associated fibroblasts had a
significantly decreased inductive signaling capability compared to
normal prostate stromal cells [34]. Genes encoding secreted
proteins ADAMTS1, IGFBP5 and WNT5A were significantly
down-regulated in NCCIT cells co-cultured with CD90+ prostate
Prostate Reactive Stroma in EAF2 Knockout Mice
PLOS ONE | www.plosone.org 10 November 2013 | Volume 8 | Issue 11 | e79542
Figure 6. Correlation of EAF2 down-regulation and vascularity in human prostate cancer tissue specimens. A. qPCR analysis of EAF2
expression in human prostate cancer tissue specimens (CaP) and normal adjacent prostate tissues (NAP). B. ADAMTS1 expression in CaP and NAP.
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cancer-associated fibroblasts compared to induction by normal
prostate stromal cells [34]. The prostates of EAF22/2 mice at 15
mos of age had decreased expression of ADAMTS1 and increased
CD90 expression. EAF2 and ADAMTS1 expression were also
decreased significantly in human prostate cancer compared to
normal adjacent tissues. EAF22/2 animals at age 19 weeks
displayed evidence of stromal inflammation, but did not express
reactive stroma marker TNC or decreased expression of
ADAMTS1, suggesting that the reactive stroma and down-
regulation of ADAMTS1 in EAF22/2 murine prostate was a
secondary effect that developed with age. Since ADAMTS1 was
not down-regulated in EAF22/2 mice at age 3 mos, it is likely that
EAF2 does not directly affect ADAMTS1 expression and that the
reactive stroma in the C57BL/6J and FVB/NJ EAF2 knockout
model is strain-specific. EAF2 expression was negatively correlated
with CD34-positive vessel density, supporting the findings in the
murine model that implicate an important role for EAF2 in
regulating prostate vascularity.
In summary, EAF2-deficient male mice on a pure C57BL/6J
and pure FVB/NJ background displayed a statistically significant
increase in PIN lesions similar to that found previously in mice on
a 129P2/OLA-C57BL/6J background. In contrast to the 129P2/
OLA-C57BL/6J genetic background, tumor incidence in other
major organs was significantly reduced in EAF22/2 mice on
C57BL/6J or FVB/NJ backgrounds. The mPIN lesions in aged
C57BL/6J and FVB/NJ EAF22/2 mice were also characterized
by a reactive stroma. C57BL/6J mice at 19 weeks of age exhibited
stromal inflammation and increased microvessel density which
preceded the development of PIN lesions and a reactive stroma.
These pathologic changes could contribute to the development of
PIN lesions and an accompanying reactive stroma in aged
EAF22/2 animals. In human prostate tissues, EAF2 expression
was positively correlated with ADAMTS1 gene expression levels
and negatively correlated with microvessel density, consistent with
the results observed in the EAF2 knockout mouse model. Future
studies will focus on elucidating the relationship between EAF2,
ADAMTS1 and the stromal microenvironment in prostate tumor
development and progression.
Supporting Information
Figure S1 Effects of EAF2 loss on C57BL/6J and FVB/NJ
mouse prostate histology. A. EAF2-deficiency induced
stromal inflammation occurred as early as 7 wks in C57BL/6J
mice. B. EAF22/2 murine prostates displayed prostate epithelial
hyperplasia (black arrow, inset), evenly distributed mild stromal
inflammation characterized by increased edema, lymphocytic
infiltration, plasma cells, neutrophils, macrophages, mast cells and
fibroblasts (dashed arrow, inset) compared to wild-type (WT) at
age 19 wks. Microvessels (black arrowhead, inset) in the prostates
of EAF22/2 mice were frequently associated with inflammation
(black arrowhead, inset). Original magnification for A and B: 10X,
inset 40X. Scale bars indicate 200 micron in 10X, 50 micron in
40X. C. CD31 immunostaining of microvessels (black arrowheads)
in transverse sections of dorsal-lateral prostate lobes from wild-
type (WT) control and EAF22/2 mice on a C57BL/6J
background at 19 weeks of age. Original magnification for C:
10X, inset 20X. Scale bars indicate 200 micron. D. Ki-67
immunostaining (black arrowheads) in transverse sections of
prostate ventral (vp) and anterior (ap) lobes from WT and
EAF22/2 FVB/NJ mice at 20 mos of age. Original magnification
20X. Scale bar represents 200 micron. E. CD31 immunostaining
of microvessels (black arrowheads) in vp from WT and EAF22/2
FVB/NJ mice at 20 mos of age. Original magnification 10X, inset
40X. Scale bars indicate 200 micron in 10X, 50 micron in 40X.
(TIF)
Figure S2 Effect of castration on C57BL/6J EAF2-
deficient mice at age 19 weeks. A. CD31 immunostaining
of microvessels (black arrowheads) in transverse sections of ventral
prostate lobes from wild-type (WT) and EAF22/2 mice on a
C57BL/6J background 14 days post-castration (Cx) at 19 weeks of
age. Original magnification 10X, inset 20X. Scale bars indicate
200 micron. B. Ki-67 immunostaining (black arrowheads) in
transverse sections of prostate anterior lobes from WT and
EAF22/2 C57BL/6J mice 14 days post-Cx at 19 weeks of age.
Original magnification 20X. Scale bars indicate 200 micron. C.
Caspase 3 immunostaining (black arrowheads) in transverse
sections of prostate anterior lobes from WT and EAF22/2
C57BL/6J mice 14 days post-Cx at 19 weeks of age. Original
magnification 20X. Scale bars indicate 200 micron.
(TIF)
Figure S3 EAF2 expression and CD34-positive micro-
vessel density in matched normal adjacent prostate and
prostate cancer tissue specimens. A. Laser capture
microdissection of prostate glandular epithelial cells for qPCR
analyses. Scale bars indicate 50 micron. B. Immunostaining
analysis of EAF2 and CD34-positive microvessels in prostate
tissues. Original magnification 10X, inset 20X. Scale bars indicate
200 micron in 10X and 200 micron in 20X.
(TIF)
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immunostaining intensity and CD34-positive microvessel density in human prostate tissue specimens. Statistical Pearson correlation was 20.651
(p = 0.003) and Spearman Coefficient was 20.623 (p = 0.006). EAF2 immunostaining intensity was negatively correlated with CD34-positive
microvessel density in human prostate tissue specimens. Immunostaining data represent 9 patients. (***p,0.0001).
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